Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 54.5268
- Book/Share 17.633
- PB 42.0522
- Debt/Equity 2.4432
- CurrentRatio 1.3723
- ROIC 0.2572
- MktCap 699116415120.0
- FreeCF/Share 0.5421
- PFCF 1434.968
- PE 59.6903
- Debt/Assets 0.4309
- DivYield 0.0076
- ROE 0.7692
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
5 Reasons It's Not Too Late to Buy Eli Lilly Stock
Published: March 20, 2025 by: The Motley Fool
Sentiment: Positive
Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable healthcare company in the world, with a market cap of $730 billion.
Read More
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
Published: March 20, 2025 by: Reuters
Sentiment: Positive
Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug regulator, it said on Thursday.
Read More
Eli Lilly: A Safe Harbor Amid Market Volatility
Published: March 17, 2025 by: Seeking Alpha
Sentiment: Neutral
My DCF analysis suggests that Eli Lilly's stock is 60% undervalued. Defensive healthcare stocks like Eli Lilly are favorable in the current uncertain macroenvironment, driven by tariff concerns and stable Fed policies. The company's robust revenue growth, high R&D spending, and strategic positioning in the GLP-1 industry underscore its long-term growth prospects.
Read More
NVO vs. LLY: Which Stock Is the Better Value Option?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novo Nordisk (NVO) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly
Published: March 14, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Final Trades: Visa, Blackstone, Eli Lilly and Invitation Homes
Published: March 13, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Lilly, J&J boosted spending on executive security after UnitedHealth shooting
Published: March 12, 2025 by: Reuters
Sentiment: Neutral
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, with both citing increased threats after a UnitedHealth insurance executive was murdered outside the company's investor meeting in December, regulatory filings show.
Read More
Eli Lilly and Company (LLY) Management presents at Leerink 2025 Global Healthcare Conference (Transcript)
Published: March 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - Head of IR Conference Call Participants Dave Risinger - Leerink Partners Dave Risinger All right. So, I think we should get started here.
Read More
Novo Nordisk Stock Drops on New Obesity Drug Finding. Eli Lilly Stands to Gain.
Published: March 10, 2025 by: Barrons
Sentiment: Negative
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
Read More
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.
Read More
2 Stocks That Could Split Very Soon
Published: March 10, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Stock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a split.
Read More
Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico by 2026, CFO says
Published: March 10, 2025 by: Reuters
Sentiment: Positive
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday at the Leerink Partners Global Healthcare Conference.
Read More
NVO, LLY and AMGN Forecast – Pharma Stocks Look Mixed in Premarket
Published: March 07, 2025 by: FXEmpire
Sentiment: Neutral
Three of the major pharma companies that I follow have shown a bit of a mixed move in the premarket hours, as the markets try to get a grip on the latest demand for GLP-1 and other medicines.
Read More
Eli Lilly Direct-To-Consumer Push Shouldn't Worry Distributors: JPMorgan
Published: March 07, 2025 by: Benzinga
Sentiment: Neutral
The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the healthcare supply chain.
Read More
US judge denies injunction to stop bar on copies of Lilly weight loss drug
Published: March 06, 2025 by: Reuters
Sentiment: Neutral
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S.
Read More
The Big 3: EBAY, SLV, LLY
Published: March 05, 2025 by: Schwab Network
Sentiment: Neutral
@Theotrade's Don Kaufman remains bullish on the iShares Silver Trust ETF (SLV) but shares bearishness on eBay Inc. (EBAY) and Eli Lilly (LLY). He also offers example options trades for all three names.
Read More
Lilly to participate in Leerink Partners Global Healthcare Conference
Published: February 28, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Feb. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Leerink Partners Global Healthcare Conference on March 10, 2025. Lucas Montarce, Lilly executive vice president and chief financial officer, will take part in a fireside chat at 9:20 a.m.
Read More
Eli Lilly investing $27B more in US manufacturing
Published: February 27, 2025 by: Fox Business
Sentiment: Positive
Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.
Read More
Eli Lilly Latest US Company to Commit to Domestic Investments
Published: February 26, 2025 by: Investopedia
Sentiment: Negative
Eli Lilly (LLY) plans to invest at least $27 billion to build four new pharmaceutical manufacturing sites in the U.S., as the company looks to ramp up its domestic drug productions amid the threat of possible tariffs.
Read More
Eli Lilly announces $27B investment in US drug manufacturing
Published: February 26, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) plans to invest at least $27 billion in four new US manufacturing facilities, the company announced during an event in Washington DC. Three of the facilities will focus on producing active pharmaceutical ingredients (APIs) for drugs like Zepbound and Mounjaro, while the fourth will expand the company's capacity for future injectable medications.
Read More
Eli Lilly to spend $27 billion to expand U.S. manufacturing with four new sites
Published: February 26, 2025 by: Market Watch
Sentiment: Positive
Eli Lilly & Co.'s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.
Read More
Eli Lilly CEO on $27 billion in new U.S. manufacturing investments
Published: February 26, 2025 by: CNBC Television
Sentiment: Positive
Eli Lilly said it will invest at least $27 billion to build four new manufacturing sites in the U.S. as demand for its weight loss and diabetes injections soars and the company develops new drugs.
Read More
Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for Self-Pay Patients
Published: February 25, 2025 by: Investopedia
Sentiment: Neutral
Eli Lilly (LLY) on Tuesday lowered the price of its weight-loss drug Zepbound for some patients paying out of pocket and introduced two new available vial doses.
Read More
Why Eli Lilly Stock Popped Today
Published: February 25, 2025 by: The Motley Fool
Sentiment: Positive
Eli Lilly (LLY 2.10%) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases.
Read More
Eli Lilly: Load Up Before It Leaves You Behind
Published: February 25, 2025 by: Seeking Alpha
Sentiment: Positive
Eli Lilly investors have been "quietly" loading up, as the stock outperformed the S&P 500. Lilly has been making gains against Novo Nordisk, and the advance may not be over. Policy risks and pricing changes could be risks to consider later, but the stock is still assessed to be undervalued when we consider LLY's PEG ratio.
Read More
Eli Lilly cuts price of weight-loss drug Zepbound for self-paying patients
Published: February 25, 2025 by: Market Watch
Sentiment: Positive
The drug company is calling on insurers and federal programs to include coverage of obesity as a chronic disease.
Read More
Eli Lilly Unveils Higher Single-Dose Zepbound Vials for $499 a Month
Published: February 25, 2025 by: Barrons
Sentiment: Positive
Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.
Read More
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
Published: February 24, 2025 by: 24/7 Wall Street
Sentiment: Negative
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was over.
Read More
This Growth Stock Surged 63% in 2024. Here's Why 2025 Could Bring An Even Bigger Gain.
Published: February 21, 2025 by: 24/7 Wall Street
Sentiment: Positive
The big pharma sector is one that's generally fallen out of favor for many investors over the past few decades, as large healthcare companies have seen slower growth and consolidation hasn't generally provided the kind of upside investors had grown accustomed to over the latter half of the past century.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO Mr. David A. Ricks
- Employees 47000